BCAB (BioAtla, Inc. Common Stock) Stock Analysis - SEC Filings

BioAtla, Inc. Common Stock (BCAB) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAB trades at $3.62 with a market cap of $6.50M and a P/E ratio of -0.73. BCAB moved -3.36% today. Year to date, BCAB is -82.97%; over the trailing twelve months it is -81.51%. Its 52-week range spans $3.26 to $126.25. Rallies surfaces BCAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find BCAB SEC filings?

Rallies organizes BCAB SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

BCAB Key Metrics

Key financial metrics for BCAB
MetricValue
Price$3.62
Market Cap$6.50M
P/E Ratio-0.73
EPS$-4.97
Dividend Yield0.00%
52-Week High$126.25
52-Week Low$3.26
Volume0
Avg Volume0
Revenue (TTM)$2.00M
Net Income$-50.62M
Gross Margin0.00%

Latest BCAB News

BCAB Analyst Consensus

BCAB analyst coverage data. Average price target: $0.00.

Common questions about BCAB

Where can I find BCAB SEC filings?
Rallies organizes BCAB SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show BCAB 10-K and 10-Q filings?
Rallies organizes BCAB SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is BCAB research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCAB. It does not provide personalized investment advice.
BCAB

BCAB